Andi Utama
National Institutes of Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Andi Utama.
Pediatrics International | 2004
Hiroyuki Shimizu; Andi Utama; Napa Onnimala; Chen Li; Zhang Li-Bi; Ma Yu-Jie; Yaowapa Pongsuwanna; Tatsuo Miyamura
Abstract Background : Recently, there have been large outbreaks of hand, foot and mouth disease (HFMD) mainly caused by enterovirus 71 (EV71) associated with severe neurological diseases in the Western Pacific Region (WPR). To monitor the realtime trend of EV71 transmission throughout the WPR, the authors conducted a molecular epidemiological analysis of EV71 infection.
Journal of Virology | 2004
Hiroyuki Shimizu; Bruce Thorley; Fem Julia Paladin; Kerri Anne Brussen; Vicki Stambos; Lilly Yuen; Andi Utama; Yoshio Tano; Minetaro Arita; Hiromu Yoshida; Tetsuo Yoneyama; Agnes Benegas; Sigrun Roesel; Mark A. Pallansch; Olen M. Kew; Tatsuo Miyamura
ABSTRACT In 2001, highly evolved type 1 circulating vaccine-derived poliovirus (cVDPV) was isolated from three acute flaccid paralysis patients and one contact from three separate communities in the Philippines. Complete genomic sequencing of these four cVDPV isolates revealed that the capsid region was derived from the Sabin 1 vaccine strain but most of the noncapsid region was derived from an unidentified enterovirus unrelated to the oral poliovirus vaccine (OPV) strains. The sequences of the cVDPV isolates were closely related to each other, and the isolates had a common recombination site. Most of the genetic and biological properties of the cVDPV isolates were indistinguishable from those of wild polioviruses. However, the most recently identified cVDPV isolate from a healthy contact retained the temperature sensitivity and partial attenuation phenotypes. The sequence relationships among the isolates and Sabin 1 suggested that cVDPV originated from an OPV dose given in 1998 to 1999 and that cVDPV circulated along a narrow chain of transmission. Type 1 cVDPV was last detected in the Philippines in September 2001, and population immunity to polio was raised by extensive OPV campaigns in late 2001 and early 2002.
Journal of Virology | 2005
Chen Fu Yang; Hour Young Chen; Jaume Jorba; Hui Chih Sun; Su Ju Yang; Hsiang Chi Lee; Yhu Chering Huang; Tzou Yien Lin; Pei-Jer Chen; Hiroyuki Shimizu; Yorihiro Nishimura; Andi Utama; Mark A. Pallansch; Tatsuo Miyamura; Olen M. Kew; Jyh Yuan Yang
ABSTRACT We determined the complete genomic sequences of nine type 1 immunodeficient vaccine-derived poliovirus (iVDPV) isolates obtained over a 337-day period from a poliomyelitis patient from Taiwan with common variable immunodeficiency. The iVDPV isolates differed from the Sabin type 1 oral poliovirus vaccine (OPV) strain at 1.84% to 3.15% of total open reading frame positions and had diverged into at least five distinct lineages. Phylogenetic analysis suggested that the chronic infection was initiated by the fifth and last OPV dose, given 567 days before onset of paralysis, and that divergence of major lineages began very early in the chronic infection. Key determinants of attenuation in Sabin 1 had reverted in the iVDPV isolates, and representative isolates of each lineage showed increased neurovirulence for PVR-Tg21 transgenic mice. None of the isolates had retained the temperature-sensitive phenotype of Sabin 1. All isolates were antigenic variants of Sabin 1, having multiple amino acid substitutions within or near neutralizing antigenic sites 1, 2, and 3a. Antigenic divergence of the iVDPV variants from Sabin 1 followed two major independent evolutionary pathways. The emergence of distinct coreplicating lineages suggests that iVDPVs can replicate for many months at separate sites in the gastrointestinal tract. Some isolates had mosaic genome structures indicative of recombination across and within lineages. iVDPV excretion apparently ceased after 30 to 35 months of chronic infection. The appearance of a chronic VDPV excretor in a tropical, developing country has important implications for the strategy to stop OPV immunization after eradication of wild polioviruses.
FEBS Letters | 2000
Andi Utama; Hiroyuki Shimizu; Shigeru Morikawa; Futoshi Hasebe; Kouichi Morita; Akira Igarashi; Masahiro Hatsu; Kazuhiro Takamizawa; Tatsuo Miyamura
The NS3 protein of Japanese encephalitis virus (JEV) contains motifs typical of RNA helicase/NTPase but no RNA helicase activity has been reported for this protein. To identify and characterize the RNA helicase activity of JEV NS3, a truncated form of the protein with a His‐tag was expressed in Escherichia coli and purified. The purified JEV NS3 protein showed an RNA helicase activity, which was dependent on divalent cations and ATP. An Asp‐285‐to‐Ala substitution in motif II of the JEV NS3 protein abolished the ATPase and RNA helicase activities. These results indicate that the C‐terminal 457 residues are sufficient to exhibit the RNA helicase activity of JEV NS3.
Japanese Journal of Infectious Diseases | 1999
Hiroyuki Shimizu; Andi Utama; Yoshii K; Yoshida H; Yoneyama T; Sinniah M; Yusof Ma; Okuno Y; Okabe N; Shih; Hsuan Yu Chen; Wang Gr; Chuan-Liang Kao; Chang Ks; Tatsuo Miyamura; Hagiwara A
Virology | 2000
Andi Utama; Hiroyuki Shimizu; Futoshi Hasebe; Kouichi Morita; Akira Igarashi; Ikuo Shoji; Yoshiharu Matsuura; Masahiro Hatsu; Kazuhiro Takamizawa; Akio Hagiwara; Tatsuo Miyamura
Microbiology Indonesia | 2010
Andi Utama; Hiroyuki Shimizu
Microbiology Indonesia | 2010
Andi Utama; Hiroyuki Shimizu
Microbiology Indonesia | 2007
Andi Utama; Hiroyuki Shimizu
Microbiology Indonesia | 2007
Andi Utama; Hiroyuki Shimizu